Novo Nordisk | NVO - Loan Capital

Stock Price
39.02
Daily Change
-1.42 -3.51%
Monthly
6.00%
Yearly
-34.80%
Q2 Forecast
38.54

Novo Nordisk reported DKK14.02B in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
ANI Pharmaceuticals USD 291.84M 5.84M Dec/2025
Aurora Cannabis CAD 33.2M 1.79M Dec/2025
Bausch Health Companies USD 20.62B 152M Dec/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Canopy Growth CAD 224.99M 1.34M Dec/2025
Drreddys Laboratories INR 129.19M 1.84M Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Merck USD 39.97B 6B Sep/2025
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Novartis USD 29.59B 5.35B Dec/2025
Novo Nordisk DKK 118.94B 29.76B Dec/2025
Novo Nordisk DKK 14.02B 224.49M Sep/2025
Pacira USD 372.19M 4.53M Dec/2025
Perrigo USD 3.6B 4.5M Dec/2025
Phibro Animal Health USD 603.6M 5.92M Dec/2025
Prestige Brands USD 1.05B 39.73M Dec/2025
Sanofi EUR 15.72B 2.45B Dec/2025
Supernus Pharmaceuticals USD 400.38M 21.13M Mar/2022
Zoetis USD 9.04B 1.97B Dec/2025